Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Surgiphor in Primary Total Shoulder Arthroplasty
NCT06601803Phase 4Enrolling by invitation
- Sponsor
- Rothman Orthopaedics
- Start
- Sep 2024
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of povidone-iodine in surgical site infection (SSI) (2 arms), sponsored by Rothman Orthopaedics. Primary endpoint: Reduction or elimination of bacteria at 90 days. Started Sep 2024; status: enrolling by invitation.
02
Drugs
povidone-iodine
03
Conditions
surgical site infection (SSI)
Beyond the preview
Go deeper on NCT06601803.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06601803.